Back to Search Start Over

Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis.

Authors :
Beyaz S
Chung C
Mou H
Bauer-Rowe KE
Xifaras ME
Ergin I
Dohnalova L
Biton M
Shekhar K
Eskiocak O
Papciak K
Ozler K
Almeqdadi M
Yueh B
Fein M
Annamalai D
Valle-Encinas E
Erdemir A
Dogum K
Shah V
Alici-Garipcan A
Meyer HV
Özata DM
Elinav E
Kucukural A
Kumar P
McAleer JP
Fox JG
Thaiss CA
Regev A
Roper J
Orkin SH
Yilmaz ÖH
Source :
Cell stem cell [Cell Stem Cell] 2021 Nov 04; Vol. 28 (11), pp. 1922-1935.e5. Date of Electronic Publication: 2021 Sep 15.
Publication Year :
2021

Abstract

Little is known about how interactions of diet, intestinal stem cells (ISCs), and immune cells affect early-stage intestinal tumorigenesis. We show that a high-fat diet (HFD) reduces the expression of the major histocompatibility complex class II (MHC class II) genes in intestinal epithelial cells, including ISCs. This decline in epithelial MHC class II expression in a HFD correlates with reduced intestinal microbiome diversity. Microbial community transfer experiments suggest that epithelial MHC class II expression is regulated by intestinal flora. Mechanistically, pattern recognition receptor (PRR) and interferon-gamma (IFNγ) signaling regulates epithelial MHC class II expression. MHC class II-negative (MHC-II-) ISCs exhibit greater tumor-initiating capacity than their MHC class II-positive (MHC-II+) counterparts upon loss of the tumor suppressor Apc coupled with a HFD, suggesting a role for epithelial MHC class II-mediated immune surveillance in suppressing tumorigenesis. ISC-specific genetic ablation of MHC class II increases tumor burden cell autonomously. Thus, HFD perturbs a microbiome-stem cell-immune cell interaction that contributes to tumor initiation in the intestine.<br />Competing Interests: Declaration of interests The authors declare no competing financial interests. S.H.O. serves as an advisory board member for Cell Stem Cell. S.B. received research funding from Elstar Therapeutics and Revitope Oncology for research that is not related to this study.<br /> (Copyright © 2021 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1875-9777
Volume :
28
Issue :
11
Database :
MEDLINE
Journal :
Cell stem cell
Publication Type :
Academic Journal
Accession number :
34529935
Full Text :
https://doi.org/10.1016/j.stem.2021.08.007